You are here:

Archived: Tipranavir (Aptivus®)


Following a full submission.

Tipranavir (Aptivus) in combination with low dose ritonavir is not recommended for use within NHS Scotland for the treatment of HIV-1 infection in highly pre-treated adult patients with virus resistant to multiple protease inhibitors.

At 48 weeks, tipranavir, in combination with low dose ritonavir, showed a significant improvement in the reduction of viral load compared with other protease inhibitor plus ritonavir regimens. Although the overall rate and type of adverse events were similar, tipranavir had a higher incidence of hepatotoxicity, hyperlipidaemia, bleeding events and rash.

Tipranavir is more expensive than other protease inhibitors and the economic case for its use has not been demonstrated

Drug Details

Drug Name: Tipranavir (Aptivus®)
SMC Drug ID: 226/05
Manufacturer: Boehringer Ingelheim Ltd
Indication: HIV
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 9 January 2006

Current Advice

Resubmission 11 September 2006